chemotherapy
The 32-gene signature showed potential in predicting South Korean gastric cancer patients' overall survival and response to chemotherapy and immunotherapy.
The firm has launched a validation trial for its in-development QuantiDNA cell-free DNA chemotherapy response assay in late-stage smoking-related cancers.
Germany Grants National Reimbursement for Three Additional Breast Cancer Biomarker Tests
Myriad Genetics' EndoPredict, Agendia's MammaPrint (distributed in Germany by PathoNext), and Veracyte's Prosigna will now be covered by public insurance.
Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test
Yourgene will provide its Elucigene DPYD tests to screen approximately 200 patients each month for the next year.
Israeli Startup Curesponse Targets European Pharma Market With Drug Prediction, Development Service
Premium
The firm's technology uses ex vivo organ culture to model cancer growth and predict a patient's tumor response to chemotherapy and targeted drugs.